【藥品庫存】 藥品安全警訊 (藥品回收)：本品一批號因主成分含量未符合規定，於2021/11/11經食藥署公告回收，院內目前使用的非回收批號。更新日期：2021/11/11。

糖尿病 (其他) Repaglinide is an oral agent of the meglitinide class used for treating noninsulin dependent diabetes mellitus.

Repaglinide has significantly reduced postprandial blood glucose in type 2 diabetes; minimal effects on fasting blood glucose were observed.

Rapidly absorbed following oral administration. Extensively metabolized in the liver and excreted predominantly via the feces; Elimination half-life: less than one hour.

Hypersensitivity to repaglinide; insulin dependent diabetes mellitus; ketoacidosis

C

Because of the potential for repaglinide to cause hypoglycemia and resultant skeletal changes in nursing infants, a decision should be made whether to discontinue nursing or the drug, taking into account the importance of the drug to the woman.

Hypoglycemia is the major adverse effect; nausea, diarrhea, constipation, vomiting, and dyspepsia were reported at a similar incidence to placebo and sulfonylureas.

0.5-4 mg PO AC; the maximum total daily dose should not exceed 16 mg